Marketing Authorisation for Prostap^® to Transfer Back to Takeda from Wyeth in the UK and Republic of Ireland

OSAKA, Japan, March 23, 2009, - Takeda Pharmaceutical Company Limited ("Takeda") today announced that it has signed an agreement with Wyeth for the product licence for Prostap^® (leuprorelin acetate), an LH-RH agonist, to transfer back to Takeda from Wyeth in the UK and Republic of Ireland.

This follows the expiry of the agreement between the two companies under which Wyeth has held the marketing authorisation for Prostap (Leuprorelin acetate) from Takeda in the UK and the Republic of Ireland since 1990.

The marketing for Prostap will now revert to Takeda from 1 July 2009. From this date, the entire Prostap product range will be marketed in the UK and Republic of Ireland by Takeda UK Limited, a wholly owned subsidiary of Takeda. Wyeth will continue to hold the marketing authorisation until this time. Both parties are working closely together to ensure a smooth transition process, in particular recognising the key importance of maintaining an uninterrupted supply of Prostap products to all patients and customers.

“The addition of Prostap will enrich our product portfolio, which currently consists of Amias^{®[ * ]}, Actos^{®[ * ]} and Competact^{®[ * ]}, and is a logical development of our plan to develop a substantial franchise in the oncology market”, commented Trevor Smith, Takeda UK’s Managing Director.

[ * ] Amias is an anti-hypertensive agent (candesartan cilexetil); Actos and Competact are anti-diabetic agents (pioglitazone HCl and pioglitazone HCl/metformin HCl respectively).

About Leuprorelin

Leuprorelin acetate, an LH-RH agonist in a sustained-release formulation, was developed using Takeda’s Drug Delivery System (DDS) technology for the treatment of prostate cancer, endometriosis and uterine fibroids and is available in a variety of formulations including once every month, three months, four months and six months. This product is marketed in around 80 countries worldwide, and is considered a gold standard therapy for prostate cancer.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.

About Takeda UK

Takeda UK Ltd is based at High Wycombe in Buckinghamshire and is the UK affiliate of Takeda Pharmaceutical Company responsible for sales and marketing of the company’s products in the UK and Ireland. More information about Takeda in the UK is available at www.takeda.co.uk.

###